

Comparison Of Pretreatment With Lignocaine And Ondansetron For Pain On Injection Of Propofol During Induction Of Anaesthesia

A Sunny, T Veerabhadraiah, S Trivikram

Citation

A Sunny, T Veerabhadraiah, S Trivikram. *Comparison Of Pretreatment With Lignocaine And Ondansetron For Pain On Injection Of Propofol During Induction Of Anaesthesia*. The Internet Journal of Anesthesiology. 2013 Volume 32 Number 1.

Abstract

Propofol causes pain on IV injection in 28%–90% of patients. A number of techniques have been tried to minimize propofol-induced pain. We compared the efficacy of pretreatment with Lignocaine 50 mg and Ondansetron 4mg after venous occlusion for prevention of propofol-induced pain. Sixty adult patients, ASA physical status I or II, undergoing elective surgery were randomly assigned into 3 groups of 20 each. Group A received normal saline, group B received lignocaine 1% (50 mg), and group C received Ondansetron 4mg. All pretreatment drugs were made in 5 mL and were accompanied by manual venous occlusion for 1 minute. Propofol was administered after release of venous occlusion. Pain was assessed with a four-point scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain at the time of propofol injection. Eighteen patients (90%) complained of pain in the group pretreated with normal saline as compared with none in Lignocaine group and Eight (40%) in Ondansetron group.

INTRODUCTION

Propofol for induction of anaesthesia causes pain or discomfort on injection in 28% - 90% of patients¹. Among 33 clinical problems, Propofol- induced pain has been ranked seventh, when both clinical importance and frequency were considered². The addition of Lidocaine to propofol reduces the incidence of pain on injection^{3,4}. However, mixtures of propofol and lidocaine are not stable and must be used within 30 minutes of preparation. Ye et al⁵ demonstrated that Ondansetron, a specific 5-Hydroxy tryptamine antagonist is 15 times more potent than lidocaine in causing numbness when injected under the skin.

With this background we conducted a placebo controlled study to compare the efficacy of Ondansetron and Lignocaine in reduction of pain on propofol injection during induction of anaesthesia.

MATERIALS AND METHODS

We included 60 adult patients, ASA (American Society of Anaesthesiologist) physical status I and II, scheduled for various elective surgical procedures under general anesthesia. The institutional ethical committee approved the study, and written, informed consent was obtained from all patients. We used a randomized, placebo controlled, double-

blinded method for evaluation. The age groups ranged from 18 to 80 years and body weight between 35 & 80kgs.

Following patients were excluded from the study:

1. Patients with disorders of lipid metabolism
2. Patients with past history of an adverse response with propofol or lignocaine.
3. Patients with history of chronic pain syndromes / analgesic drugs.
4. Patients with history of convulsions, head injury.
7. Patients with cardiac conduction defects or on anti-arrhythmic drugs
8. Patients with difficult airway.
9. Pregnant and lactating mothers

All subjects received 5-10mg oral diazepam as premedication the night before and 2 hours before induction of anesthesia on the day of surgery with sips of water. During induction of anesthesia, patients were monitored with Electro cardiogram, Pulse oximetry, and non-invasive blood pressure.

The patients were then allocated randomly to one of three groups.

Group A – 5ml of 0.9% sodium chloride

Group B- 50mg Lignocaine (5ml of 1% solution)

Group C-4mg Ondansetron (OND) (diluted to 5ml)

Each patient received 5 mL of pretreatment solution (0.9% saline or 1% Lignocaine or Ondansetron 4 mg) Intravenous, followed by anesthetic induction with propofol 2.5 mg/kg (Propofol preparation used for all the cases were the same). The solutions were prepared by an independent anesthesiologist, and the investigator did not know the contents of the solutions. The patients received 5 mL of the pretreatment solution over a period of 20s while the venous drainage was occluded manually at midarm by an assistant⁶. The occlusion was released after 1 minute, and one fourth of the total calculated dose of propofol was administered for a period of 5seconds. No analgesic drug was given before propofol. The level of pain was assessed by a second, independent anesthesiologist who was unaware of the group to which the patient had been allocated. The patients were asked a standard question about the comfort of the injection; the verbal response and behavioral signs, such as facial grimacing, arm withdrawal, or tears, were noted¹. A score of 0–3, which corresponded to no pain or mild, moderate, and severe pain, was recorded (Table1).

Adverse effects, if any, were noted. Induction of anesthesia was continued with propofol. Tracheal intubation was facilitated with Pancuronium, and anesthesia was maintained with inhaled technique supplemented with fentanyl¹. Monitoring during anaesthesia was continued with Electrocardiogram, Pulse Oximetry and Non-invasive blood pressure measurement. After the completion of surgical procedure, residual neuromuscular blockade was antagonised with 0.05mg/kg of Neostigmine and 0.02mg/kg of Atropine. Extubation was done when the patients were fully awake and obeying commands. The data obtained were analyzed statistically using the chi-square test. A p value of <0.05 was accepted as statistically significant.

ResultsThe ratio of men to women was 1.2:1. Age ranged from 18 to 80 years and the body weight ranged from 35 to 80 kgs. There was no significant difference between the two groups with regard to sex, age or weight ($p>0.05$). When pain score was analysed it was found that only 10% of patients in saline group had no pain(score of 0), 20% had moderate pain(score 2) and 70% had severe pain(score 3). In Ondansetron group 60% had no pain (score 0) & 40% had mild pain (score 1); moderate (score 2) and severe pain(score 3) was not noticed in this group. All the patients in Lignocaine group had a score of 0 (no pain) (Table 2).

Severity of pain was much less with Ondansetron and Lignocaine group than saline group. Pain score of 3 & 4

(moderate pain & severe pain) was not noticed in Ondansetron and Lignocaine group. 40% of patients in Ondansetron group had mild pain whereas none in Lignocaine group had.

After Propofol, one patient in the saline group had myoclonic movements and 10% (2 patients) in Ondansetron group had skin rashes in the limb into which Propofol was injected which was self limiting (Table:3). Statistical analysis revealed it to be insignificant ($p>0.05$)

Table 1

Assessment of Pain during Injection of Propofol

Table 2

Pain after propofol

		Drug			Total
		Placebo	Ondansetron	Lignocaine	
painprof	-				
	Count	2	12	20	34
	%	10.0%	60.0%	100.0%	56.7%
	+				
	Count	0	8	0	8
	%	.0%	40.0%	.0%	13.3%
	++				
	Count	4	0	0	4
	%	20.0%	.0%	.0%	6.7%
	+++				
	Count	14	0	0	14
	%	70.0%	.0%	.0%	23.3%
Total		20	20	20	60
		100.0%	100.0%	100.0%	100.0%

a. $\chi^2=66.353$ $P<0.001$ VHS

(VHS= very highly significant)

Table 3

Side effects

		Drug			Total
		Placebo	Ondansetron	Lignocaine	
NIL	Count	19	18	20	57
	%	95.0%	90.0%	100.0%	95.0%
Myoclonus	Count	1	0	0	1
	%	5.0%	.0%	.0%	1.7%
Rashes	Count	0	2	0	2
	%	.0%	10.0%	.0%	3.3%
Total		20	20	20	60
		100.0%	100.0%	100.0%	100.0%

a. $\chi^2=6.105$ $P=.191$ NS

NS: not significant

DISCUSSION

In our study, we observed that pretreatment with Lignocaine 50mg or Ondansetron 4mg attenuated pain associated with Propofol injection. However Lignocaine was found to be slightly better than Ondansetron in reducing pain.

Chemically, propofol belongs to the group of sterically hindered phenols. Hence, like the phenols, propofol irritates the skin, mucous membrane and venous intima. Propofol causes pain on injection in 45-75% of patients, particularly when it is administered through the small veins at the back of the hand⁷. Various ways of minimizing this pain have been proposed, including using larger veins⁸, priming with lidocaine, an opioid (e.g., fentanyl, alfentanil, or meperidine), or midazolam before the injection of propofol^{7,9} diluting propofol with 5% glucose or 10% intralipid, injecting cold saline with the propofol or discontinuing fluid during the injection¹⁰, or the use of 5-hydroxytryptamine₃ antagonists¹¹.

Bradykinin, by producing local venous vasodilation and hyperpermeability, may increase the contact between the aqueous phase propofol and free nerve endings resulting in pain on injection¹².

McCulloch MJ, Lees NW et al¹³ showed that Lidocaine pretreatment reduces the incidence of pain to 17.5% and 19.5% respectively. Others have shown that freshly mixed propofol and 1% lidocaine reduces the incidence of pain on injection significantly. In our study, all the patients in Lignocaine group had a score of 0 (no pain).

Ye et al.⁵ found, in rats, that Ondansetron is approximately 15 times more potent as local anesthetic than lidocaine. The local anesthetics currently in use contain hydrophilic and hydrophobic structures, separated by an intermediate amide or ester linkage. The hydrophilic group can be a tertiary or secondary amine; the hydrophobic domain must always be an aromatic moiety. Although Ondansetron does not have this aromatic moiety, it has the ability to block sodium channels. Peripheral 5-Hydroxytryptamine₃ receptors involve nociceptive pathways⁵. Recently, Ondansetron has demonstrated binding at the opioid μ receptors in humans and exhibits agonist activity¹⁴. As a result of its multifaceted actions as a sodium channel blocker, a 5-Hydroxytryptamine₃ receptor antagonist, and μ -opioid agonist, Ondansetron may potentially be used to alleviate pain produced by a drug similar to propofol. The usual dose of Ondansetron in adults is 4 mg. Pretreatment with the usual dose of Ondansetron could alleviate the pain produced by propofol, and one minute was allowed for its action to begin. We chose a one-

minute interval with the presumption that this period might be sufficient, as most patients feel numbness after the intradermal injection of a local anesthetic. In our study, 40% of patients in Ondansetron group had mild pain whereas none in Lignocaine group had any pain.

CONCLUSION

Though control of pain was better with Lignocaine, Ondansetron had no untoward side effects and can be used as an alternative to Lignocaine in reducing pain on propofol injection.

References

1. Nathanson MH, Gajraj NM, Russell JA. Prevention of pain on injection of propofol : a comparison of lidocaine with alfentanil. *Anesth Analg* 1996;82:469-71
2. Banssillon V. Douleur à l'injection du Diprivan. *Réanim* 1994;13:465-70.
3. Gehan G, Karoubi P, Quinet F, et al. Optimal dose of lignocaine for preventing pain on injection of propofol. *Br J Anaesth* 1991;66:324-6
4. King SY, Davis FM, Wells JE, et al. Lidocaine for the prevention of pain due to injection of propofol. *Anesth Analg* 1992;74:246-9
5. Ye JH, Mui WC, Ren J, et al. Ondansetron exhibits the properties of a local anesthetic. *Anesth Analg* 1997;85:1116-21
6. Porteous R. Pain-free intravenous injections [letter]. *Anaesthesia* 1987;42:1021
7. Cameron E, Johnston G, Crofts S, Morton NS. The minimum effective dose of lignocaine to prevent injection pain due to propofol in children. *Anaesthesia* 1992; 47: 604-6
8. Seki S, Sekine R, Aketa K, et al. Induction of anesthesia with propofol injected through a central catheter. *Masui* 1999; 48: 62-6
9. Hillier SC. Monitored anesthesia care. In: Barash PG, Cullen BF, Stoelting RK, eds. *Clinical anesthesia*. 3rd ed. Philadelphia, PA: Lippincott-Raven, 1996: 1159-71.
10. Nakane M, Iwama H. A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. *Br J Anaesth* 1999; 83: 397-404
11. Cox JA, Lysko PG, Henneberry RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: role of the voltage-dependent magnesium block. *Brain Res* 1989; 499: 267-72.
12. Brooker J, Hull CJ, Stafford M. Effect of lignocaine on pain caused by propofol injection. *Anaesthesia* 1985;40:91-2.
13. McCulloch MJ, Lees NW. Assessment and modification of pain on induction with propofol (Diprivan). *Anaesthesia* 1985;40:1117-20
14. Gregory RE, Ettinger DS. 5-HT₃ receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting : a comparison of their pharmacology and clinical efficacy. *Drugs* 1998;55:173-89

Author Information

Alex Sunny, MD, Assistant Professor

Department of Anaesthesiology, KMCT Medical College

Calicut, Kerala state. India

sunnex76@hotmail.com

T.A Veerabhadraiah, DA

Department of Anaesthesiology, KMC Medical College

Mangalore, Karnataka, India

Shenoy Trivikram, MD

Department of Anaesthesiology, KMC Medical College

Mangalore, Karnataka, India